Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $118.67 Average Price Target from Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $118.6667.

A number of analysts recently issued reports on MNPR shares. HC Wainwright raised their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Finally, Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $109.00 to $119.00 in a research note on Thursday, August 13th.

Insider Buying and Selling at Monopar Therapeutics

In other news, Director Kim R. Tsuchimoto sold 4,090 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. This represents a 35.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the transaction, the director owned 23,751 shares of the company’s stock, valued at $2,654,649.27. The trade was a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new position in shares of Monopar Therapeutics in the first quarter worth about $673,000. Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics in the first quarter valued at approximately $377,000. Geode Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after buying an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in Monopar Therapeutics in the 2nd quarter worth approximately $209,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Trading Down 1.8%

Shares of MNPR opened at $111.89 on Friday. The company has a market capitalization of $750.78 million, a price-to-earnings ratio of -51.56 and a beta of 1.47. The stock has a 50 day moving average of $106.44 and a 200 day moving average of $75.00. Monopar Therapeutics has a 12 month low of $32.77 and a 12 month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts predict that Monopar Therapeutics will post -2.94 earnings per share for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.